Rapport Therapeutics, Inc. Depreciation
Rapport Therapeutics, Inc. (RAPP) reported Depreciation of $400.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-08-05
- Rapport Therapeutics, Inc. depreciation for the quarter ending 2026-06-30 was $200.00K, a 33.33% decline year-over-year.
- Rapport Therapeutics, Inc. depreciation for the quarter ending 2026-03-31 was $200.00K, a 0.00% change year-over-year.
- Rapport Therapeutics, Inc. depreciation for the quarter ending 2025-12-31 was $200.00K, a 0.00% change year-over-year.
- Rapport Therapeutics, Inc. depreciation for the quarter ending 2025-09-30 was $300.00K, a 50.00% increase year-over-year.
- Rapport Therapeutics, Inc. depreciation for fiscal 2025 was $1.00M, a 25.00% increase from fiscal 2024.
- Rapport Therapeutics, Inc. depreciation for fiscal 2024 was $800.00K, a 700.00% increase from fiscal 2023.
- Rapport Therapeutics, Inc. depreciation for fiscal 2023 was $100.00K.
| Period end | Depreciation 3 month | Depreciation 6 month | Depreciation 9 month | Depreciation 12 month |
|---|---|---|---|---|
| 2026-06-30 | $200.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $400.00K 10-Q · filed 2026-08-05 | $600.00K derived: sum of 3 quarters · filed 2026-08-05 | $900.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $200.00K 10-Q · filed 2026-05-07 | $400.00K derived: sum of 2 quarters · filed 2026-05-07 | $700.00K derived: sum of 3 quarters · filed 2026-05-07 | $1.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $500.00K derived: sum of 2 quarters · filed 2026-03-10 | $800.00K derived: sum of 3 quarters · filed 2026-08-05 | $1.00M 10-K · filed 2026-03-10 |
| 2025-09-30 | $300.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $600.00K derived: sum of 2 quarters · filed 2026-08-05 | $800.00K 10-Q · filed 2025-11-06 | $1.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $300.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $500.00K 10-Q · filed 2026-08-05 | $700.00K derived: sum of 3 quarters · filed 2026-08-05 | $900.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $200.00K 10-Q · filed 2026-05-07 | $400.00K derived: sum of 2 quarters · filed 2026-05-07 | $600.00K derived: sum of 3 quarters · filed 2026-05-07 | $800.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $400.00K derived: sum of 2 quarters · filed 2026-03-10 | $600.00K derived: sum of 3 quarters · filed 2026-03-10 | $800.00K 10-K · filed 2026-03-10 |
| 2024-09-30 | $200.00K 10-Q · filed 2024-11-07 | $400.00K derived: sum of 2 quarters · filed 2024-11-07 | $600.00K 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $200.00K 10-Q · filed 2024-08-08 | $400.00K 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | $200.00K 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | $100.00K 10-K · filed 2025-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |